Nuvation Bio (Nuvation Bio) Accounts Payable & Accrued Expense : $7.65 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Accounts Payable & Accrued Expense?

Nuvation Bio's quarterly accounts payable & accrued expense increased from Jun. 2023 ($12.13 Mil) to Sep. 2023 ($14.23 Mil) but then declined from Sep. 2023 ($14.23 Mil) to Dec. 2023 ($7.65 Mil).

Nuvation Bio's annual accounts payable & accrued expense declined from Dec. 2021 ($9.90 Mil) to Dec. 2022 ($7.97 Mil) and declined from Dec. 2022 ($7.97 Mil) to Dec. 2023 ($7.65 Mil).

Nuvation Bio Accounts Payable & Accrued Expense Historical Data

The historical data trend for Nuvation Bio's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Accounts Payable & Accrued Expense Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

3.32

9.90

7.97

7.65

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial											7.97	11.31	12.13	14.23	7.65

Nuvation Bio Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).